News Release锛�2020 | 亚洲彩票官网., Ltd.

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2020 Release

December 18, 2020

EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA庐
December 16, 2020

LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study
First Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer
December 10, 2020

BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN
If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer鈥檚 disease
Aducanumab is now under regulatory review in Japan, Europe and the United States
December 4, 2020

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
November 30, 2020

EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of伪-synuclein misfolding and aggregation
November 30, 2020

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
November 27, 2020

AbbVie and 亚洲彩票官网 Announce an approval for additional indication of HUMIRA庐, a fully Human Anti-TNF伪 Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
November 26, 2020

EISAI COMMENCES 鈥淧aDiCo鈥� SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSON鈥橲 DISEASE
WITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS
November 18, 2020

EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME
November 18, 2020

JYSELECA庐 (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN
A once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies
November 16, 2020

EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA庐 FOR USE IN PEDIATRIC PATIENTS
November 10, 2020

LENVIMA庐 Plus KEYTRUDA庐 Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA庐 Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib
Results of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at